Adeno-associated virus as a vector for liver-directed gene therapy

Area of Science:

• Gene therapy
• Hepatocyte-targeted treatments
• Viral vector applications

Background:

• Adeno-associated virus (AAV) vectors are being explored for liver-directed gene therapy.
• Successful application requires understanding factors influencing vector efficacy and expression levels.

Purpose of the Study:

• To evaluate factors critical for successful adeno-associated virus (AAV) vector application in liver-directed gene therapy.
• To assess the impact of different promoters on gene expression in hepatocytes.

Main Methods:

• Injection of AAV vectors with varying promoters driving human alpha-1-antitrypsin (alpha-1AT) expression into the portal circulation of immunodeficient mice.
• Analysis of alpha-1AT expression stability and levels.
• Southern blot analysis of liver DNA to quantify provirus integration.
• In situ hybridization and immunohistochemical analysis to determine expression patterns in hepatocytes.

Main Results:

• Stable, yet promoter-dependent, alpha-1-antitrypsin expression was observed.
• Liver DNA analysis indicated approximately 0.1 to 2.0 provirus copies per diploid genome, forming head-to-tail concatamers.
• Expression was detected in approximately 5% of hepatocytes, primarily localized in the pericentral region.

Conclusions:

• Adeno-associated virus (AAV) vectors are a viable option for gene therapy targeting hepatocytes.
• The choice of promoter significantly influences the level of gene expression.
• Further research can optimize AAV vector strategies for treating liver diseases.